Wyeth

Albert John Molinari

Mark Anthony Ashwell

Eugene John Trybulski

Amedeo A Failli

Dominick Anthony Quagliato

William Ronald Solvibile

William Jay Moore

Jay Donald Albright

John P Dusza

Robert J Steffan

Thomas Joseph Caggiano

Jehan F Bagli

Brian Hugh Ridgway

Mark Antony Ashwell

Peter S Chan

The present invention relates generally to phenanthridine carbonyl compositions such as substituted phenanthridine carbonyl phenols of Formula 1: wherein Rto Rare as defined in the specification, or pharmaceutically acceptable salts thereof; and methods of using them.

Phenanthridine carbonyl phenols

Novel compounds of Formula (I) and pharmaceutically acceptable salts thereof, and pharmaceutical formulations containing such compounds which are useful as anti-aquaretic agents in the treatment of nocturnal urinary enuresis, nocturnal urinary urgency, and/or similar conditions.

Biologically active vasopressin agonist metabolites

This invention provides a compound of formulae (I) or (II) having the structureor a pharmaceutically acceptable salt thereof which are useful for the treatment of the inflammatory component of diseases and are particularly useful in treating atherosclerosis, myocardial infarction, congestive heart failure, inflammatory bowel disease, arthritis, type II diabetes, and autoimmune diseases such as multiple sclerosis and rheumatiod arthritis.

Substituted dihydrophenanthridinesulfonamides

Heterocyclic beta-3 adrenergic receptor agonists

Tricyclic vasopressin agonists

Heterocyclic &bgr;-3 adrenergic receptor agonists

Growing community of inventors

Pottstown, PA, United States of America

Albert John Molinari